Verisee Software for Diabetic Retinopathy Screening
Last updated on July 2021Recruitment
- Recruitment Status
- Not yet recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Diabetic Retinopathy
- Type
- Interventional
- Phase
- Not Applicable
- Design
- Allocation: N/AIntervention Model: Single Group AssignmentIntervention Model Description: Examine the diagnostic accuracy in referred participantsMasking: None (Open Label)Primary Purpose: Screening
Participation Requirements
- Age
- Between 20 years and 125 years
- Gender
- Both males and females
Description
Diabetic retinopathy (DR) is the leading cause of blindness among working-age patients with type 2 diabetes. According to previous studies, early screening and timely treatment can reduce the risk of worsening DR and blindness. International guidelines recommend that screening for DR be performed at...
Diabetic retinopathy (DR) is the leading cause of blindness among working-age patients with type 2 diabetes. According to previous studies, early screening and timely treatment can reduce the risk of worsening DR and blindness. International guidelines recommend that screening for DR be performed at least once every year for patients with type 2 diabetes. The investigators will implement a validated deep learning-based software, VeriSee®, in clinics, and evaluate the benefits on diagnostic accuracy and the clinical referral rate for diabetic retinopathy after implementation of this software.
Tracking Information
- NCT #
- NCT04631653
- Collaborators
- Not Provided
- Investigators
- Principal Investigator: I-Te Lee, MD,PhD Taichung Veterans General Hospital
Get Well Soon